Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CymaBay Therapeutics, Inc.CBAY · Entity 92768 | Chief Commercial Officer | January 25, 2023 | January 27, 2023 |
| Stablecoin Development CorpNBY · Entity 7283 | Chief Commercial Officer | December 14, 2017 | January 08, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CymaBay Therapeutics, Inc.
Report date January 25, 2023 · Filed January 27, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.80 · Expires 2033-01-24 | Direct | 215,000 |
Reported balance
After 2023-01-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-01-25 · Grant · Acquired 215,000 · Balance 215,000 F1: The option vests as to 1/48 of the underlying shares monthly from January 1, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests as to 1/48 of the underlying shares monthly from January 1, 2023.
Stablecoin Development Corp
Report date December 14, 2017 · Filed January 08, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $3.42 · Expires 2027-12-14 | Direct | 10,000 |
Reported balance
After 2017-12-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-12-14 · Grant · Acquired 10,000 · Balance 10,000 F1: Granted pursuant to the 2017 Omnibus Incentive Plan F2: Vesting will occur only if performance criteria are met and certified by the Compensation Committee before August 1, 2018 |
Filing footnotes · ownership attribution and instrument terms
F1: Granted pursuant to the 2017 Omnibus Incentive Plan
F2: Vesting will occur only if performance criteria are met and certified by the Compensation Committee before August 1, 2018
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 25, 2023 Filed Jan 27, 2023 16:26 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | GrantEmployee Stock Option (right to buy) · Derivative | 215,000 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001062993-23-001490 · form4.xml · derivative · entry 1 STUART LEWIS J · CIK 0001407368 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,000 Underlying: Common Stock · 215,000 shares Expires 2033-01-24 F1 · derivative.exercise_date: The option vests as to 1/48 of the underlying shares monthly from January 1, 2023. Read SEC document |
| January 25, 2022 Filed Jan 27, 2022 16:56 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | GrantEmployee Stock Option (right to buy) · Derivative | 116,667 | $0.00 Strike: $2.94 | $0.00 |
DisclosureSEC source: 0001062993-22-001700 · form4.xml · derivative · entry 1 STUART LEWIS J · CIK 0001407368 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,667 Underlying: Common Stock · 116,667 shares Expires 2032-01-24 F1 · derivative.exercise_date: The option vests as to 1/48 of the underlying shares monthly from January 1, 2022. Read SEC document |
| May 10, 2021 Filed May 10, 2021 17:55 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | GrantEmployee Stock Option (right to buy) · Derivative | 360,000 | $0.00 Strike: $3.94 | $0.00 |
DisclosureSEC source: 0001062993-21-004321 · form4.xml · derivative · entry 1 STUART LEWIS J · CIK 0001407368 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 360,000 Underlying: Common Stock · 360,000 shares Expires 2031-05-09 F1 · derivative.exercise_date: The option vests as to 1/4 of the underlying shares on May 10, 2022 and vests as to 1/48 of the underlying shares monthly thereafter. Read SEC document |
| December 14, 2017 Filed Jan 8, 2018 18:29 UTC | Stablecoin Development Corp NBY · Entity 7283 | GrantRestricted Stock Unit · Derivative | 10,000 | $0.00 Strike: $3.42 | $0.00 |
DisclosureSEC source: 0001437749-18-000425 · rdgdoc.xml · derivative · entry 1 STUART LEWIS J · CIK 0001407368 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: common stock · 10,000 shares Expires 2027-12-14 F1 · security: Granted pursuant to the 2017 Omnibus Incentive Plan F2 · derivative.exercise_date: Vesting will occur only if performance criteria are met and certified by the Compensation Committee before August 1, 2018 Read SEC document |
| December 14, 2017 Filed Jan 8, 2018 18:21 UTC | Stablecoin Development Corp NBY · Entity 7283 | Grantstock option (right to buy) · Derivative | 100,000 | $0.00 Strike: $3.42 | $0.00 |
DisclosureSEC source: 0001437749-18-000424 · rdgdoc.xml · derivative · entry 1 STUART LEWIS J · CIK 0001407368 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: common stock · 100,000 shares Expires 2027-12-14 F1 · security: Granted pursuant to the 2017 Omnibus Incentive Plan F2 · derivative.exercise_date: 25% will vest on the first anniversary of the grant date, vesting quarterly thereafter over the next three years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.